Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Caris Life Sciences and Flatiron Health Collaborate to Establish a Comprehensive Real-World Oncology Database

NextEdge Admin

14 Dec 2023

2 min 7 sec

Caris Life Sciences and Flatiron Health announced a strategic collaboration on Monday, aiming to merge their extensive databases of real-world multimodal data to propel advancements in the field of oncology drug development.

As part of the partnership, Caris will contribute its comprehensive genomic, transcriptomic, proteomic, and imaging database, boasting over 50 petabytes of oncology-specific data. Notably, Caris possesses whole-exome sequencing DNA coverage and whole-transcriptome sequencing RNA coverage for every patient tested using its cutting-edge technology.

In tandem, Flatiron Health, a subsidiary of Roche, will bring its repository of longitudinal patient data, inclusive of crucial clinical outcomes. The collaborative effort will enable biopharmaceutical companies to leverage the amalgamated database, facilitating more informed decisions in the realm of personalized drug development.

Brian Lamon, Chief Business Officer at Caris, emphasized the significance of overcoming the challenge of identifying an adequate number of records for building cohorts to address pivotal research questions within the oncology community. He stated, “With Caris and Flatiron’s combined strength and expansive reach across oncology, we can provide this incredibly powerful data at a scale that will fuel drug discovery and therapeutic innovation.”

While specific details and terms of the agreement were not disclosed by the companies, the collaboration underscores a concerted effort to harness collective expertise and resources for advancing oncological research.